Search
Turmeric
go.drugbank.com/drugs/DB14276ApprovedInvestigationalTurmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Yu JinTazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigational[L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476] … Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Piperazine
go.drugbank.com/drugs/DB00592ApprovedVet approvedWithdrawnPiperazine was first introduced as an anthelmintic in 1953. … First used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953.
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies. … [L53743] ITP is an autoimmune disorder characterized by low platelet count.
Phenylacetic acid
go.drugbank.com/drugs/DB09269ApprovedBecause it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China. … Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.
Categories: Ammonium Ion Binding ActivityEnsifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigational[L50903] It works to induce bronchodilator and reduce inflammation in COPD.[A263913] … Ensifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes.
Synonyms: N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREA, UREA, N-(2-(6,7-DIHYDRO-9,10-DIMETHOXY-4-OXO-2-((2,4,6-TRIMETHYLPHENYL)IMINO)-2H-PYRIMIDO(6,1-A)ISOQUINOLIN-3(4H)-YL)ETHYL)-Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[A264199] Upon administration, PTH is cleaved from palopegteriparatide in a controlled manner to achieve a continuous systemic exposure of active PTH. … Palopegteriparatide is a parathyroid hormone (PTH) analog.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleGaretosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940,L64047] It is the second therapy approved for FOP, following [palovarotene] (Sohonos), which was approved in 2023, and is the first FOP therapy shown to reduce clinician-assessed flare-ups. … [L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic
Clofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnIt was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. … [A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.